T-cell malignant tumors are characterized by high malignancy and poor prognosis. Hematopoietic stem cell transplantation is the most effective treatment approach in relapsed or refractory T-cell malignancies, which is often accompanied by severe transplantation-associated complications. Therefore, it is urgent to explore safe and effective therapies. Chimeric antigen receptor T cell therapy (CAR-T cell therapy), as a relatively novel immunotherapy method, has achieved great clinical benefits in relapsed or refractory B cell malignant tumor and multiple myeloma. Up to now, eight related drugs have been approved (6 approved by FDA and 8 approved by CFDA). However, for T-cell malignant tumors, CAR-T cell immunotherapy is still in the stages of preclinical and (or) early clinical, and faces many difficulties and challenges. This article reviewed the current research progress of CAR-T cell therapy for T cell malignancies.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |